# Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

> **NCT02631499** · PHASE4 · UNKNOWN · sponsor: **Fudan University** · enrollment: 256 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Neoplastic Cells, Circulating

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Epirubicin
- **DRUG:** lipiodol

## Key facts

- **NCT ID:** NCT02631499
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2015-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631499, "Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02631499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*